Although G-protein-coupled receptor kinase 2 (GRK2) is the most widely studied member of a family of kinases that has been shown to exert powerful influences on a variety of G-protein-coupled receptors, its role in the brain remains largely unknown. Here we report the localization of GRK2 in the mouse brain and generate novel conditional knock-out (KO) mice to assess the physiological importance of this kinase in cholinergic neurons. Mice with the selective deletion of GRK2 in this cell population (ChAT IRES-cre Grk2 f/f KO mice) exhibit reduced behavioral responsiveness to challenge with oxotremorine-M (Oxo-M), a nonselective muscarinic acetylcholine receptor agonist. Specifically, Oxo-M-induced hypothermia, hypolocomotion, and salivation were markedly reduced in these animals, while analgesic responses were unaltered. In contrast, we found that GRK2 deficiency in cholinergic neurons does not alter cocaine-induced psychomotor activation, behavioral sensitization, or conditioned place preference. These results demonstrate that the elimination of GRK2 in cholinergic neurons reduces sensitivity to select muscarinic-mediated behaviors, while dopaminergic effects remain intact and further suggests that GRK2 may selectively impair muscarinic acetylcholine receptor-mediated function in vivo.
Introduction
Regulation of G-protein-coupled receptor (GPCR)-mediated signaling and trafficking by G-protein-coupled receptor kinases (GRKs) is fundamental to many diverse neurobiological processes. This family of kinases consists of seven distinct members (GRK1-7), all of which have been shown to promote GPCR desensitization via phosphorylation of the agonist-activated receptor. Five of the GRKs (GRK2-6) are expressed to varied extents in the brain (Premont and Gainetdinov, 2007) . Germline deletion of GRK5 or GRK6 in mice results in a myriad of centrally mediated phenotypes including altered sensitivity to muscarinic agonists, psychostimulants, and antipsychotic drugs (Gainetdinov et al., 1999 Raehal et al., 2009; Managò et al., 2012) . GRK2 is unique within this family because it is the only isoform whose germline deletion in mice results in embryonic lethality, leaving the physiologic function of GRK2 in the adult brain relatively unknown (Jaber et al., 1996) . Several studies have reported brain region-specific changes in GRK2 expression levels following pharmacological treatments that target the dopamine system, such as 6-hydroxydopamine and cocaine (Bezard et al., 2005; Ahmed et al., 2008b; Schroeder et al., 2009 ). In addition, increased GRK2 levels were also reported in the frontal cortex of fragile X mental retardation protein (FMRP)-deficient mice (Wang et al., 2008) . However, the physiological consequences of altered GRK2 levels are unclear in most of these contexts and the role of GRK2 in the expression of dopamine-associated behaviors has never been thoroughly investigated. Furthermore, given the lack of information regarding the cellular populations containing GRK2 in the brain, it is difficult to pinpoint the principal cell type in which these changes are occurring.
In this study, we report the expression pattern of GRK2 throughout the mouse brain and demonstrate that within the striatum, GRK2 is predominantly expressed in cholinergic interneurons. To better understand the role of GRK2 in cholinergic neurons, we generated conditional knock-out (KO) mice and performed behavioral analyses on naive and drug-stimulated animals. We demonstrate that GRK2 deficiency does not grossly alter the behavior of these animals but, rather, results in a marked reduction in responsiveness to muscarinic receptor stimulation.
Materials and Methods
Animals. All animal studies were conducted with an approved protocol from the Duke University Institutional Animal Care and Use Committee in accordance with National Institutes of Health guidelines. C57BL/6J and ChAT IRES-cre mice (stock #006410) were purchased from Jackson Laboratories. Floxed Grk2 mice were obtained from Dr. Gerald Dorn II (Washington University, St Louis, Missouri) (Matkovich et al., 2006) and Rosa26-floxed-stop-EYFP reporter mice were obtained from Dr. Brigid Hogan (Duke University). Experimental animals were generated by crossing homozygous floxed mice to homozygous floxed mice that were also heterozygous for cre (Grk2
mice (KO animals) and Grk2 f/f littermates (control animals). Drugand experiment-naive adult mice (2-6 months of age and of mixed sex) were used for all studies.
Drugs. Cocaine hydrochloride and Oxotremorine-M were purchased from Sigma-Aldrich and Tocris Biosciences, respectively. Drugs were dissolved in sterile isotonic saline and injected as described at a volume of 10 ml/kg body weight.
Immunohistochemistry. Staining was performed as previously described (Daigle et al., 2011) . Briefly, mice were anesthetized and brains were then fixed by transcardial perfusion of ice-cold PBS followed by 10% formalin solution (Sigma-Aldrich). Free-floating brain sections (50 m) were prepared and incubated overnight at 4°C in the indicated primary antibody. The primary antibodies used were as follows: GRK2 (1:500; Santa Cruz Biotechnology), DARPP-32 (dopamine-and cAMPregulated phosphoprotein of 32 kDa) (1:2000; BD Biosciences), ChAT (choline acetyltransferase) (1:300; Millipore), and GFP (1:5000; Abcam). Alexa dye-conjugated secondary antibodies (Life Technologies) were used to detect the primary antibody. Images (1024 ϫ 1024 pixels) were acquired on an Olympus FluoView FV1000 confocal microscope.
Western analyses. Measurement of GRK2 levels in lysates from the indicated brain regions was performed as previously described (Daigle et al., 2011) .
Behavioral analyses. All oxotremorine-M (Oxo-M) behavioral experiments were performed blind of genotype. For these studies, body temperature, spontaneous and drug-induced locomotor activity, and antinociceptive responses were measured as previously described (Daigle et al., 2011) .
Locomotor activity. Locomotor activity was measured at 5 min intervals during the light phase of the cycle in an automated Omnitech Digiscan apparatus (Accuscan Instruments). Cocaine sensitization experiments were performed as previously described . Briefly, mice were given one injection of cocaine and then placed into the open field where activity was monitored for 90 min, for five consecutive days. After a 1 d reprieve from treatment, mice were challenged on day 7 with the same dose of cocaine and again monitored in the open field.
Conditioned place preference. Conditioned place preference (CPP) was performed in a three-chamber apparatus (Med Associates) as previously described . In brief, the CPP protocol consisted of preconditioning, conditioning, and postconditioning phases. During the preconditioning phase on day 1, mice were allowed free access to all three chambers and the time spent in each compartment for a 30 min period was recorded. During the conditioning phase, mice were injected with cocaine (10 or 20 mg/kg, i.p.) on days 2, 4, and 6 and with saline on days 3, 5, and 7. The drug was randomly paired with alternating compartments, such that half of the mice received drug in one distinct compartment and the other half received drug in a different distinct compartment. On day 8 (postconditioning phase), mice were allowed free access to all three chambers and the time spent in each individual chamber was recorded for a 30 min period. Cocaine preference was determined by calculating the difference (⌬) in the time spent in the drug-paired chamber during the preconditioning period to the time spent in the same chamber during the postconditioning period.
Measurement of body temperature. Rectal body temperature was measured by inserting a probe from a digital thermometer (TH8, Physitemp) into the rectum.
Salivation. Salivation was measured as previously described (Gainetdinov et al., 1999; Gomeza et al., 1999b) . Scoring for salivation was designated as follows: 0 ϭ no salivation, 1 ϭ moderate salivation, and 2 ϭ pronounced salivation. Scores were normalized to 100% (score of 2) and averaged for each time point according to genotype.
Hot plate analgesia test. Analgesic responses were determined using a hot plate maintained at 58 Ϯ 1°C. Animals were exposed to the hot plate and the time that elapsed until the animal responded was recorded.
Statistical analyses. All statistical analyses were performed using GraphPad Prism 4.0 software (GraphPad Software) and the results are presented as means and SEMs. A one-way or two-way ANOVA alone or with repeated measures followed was used for comparisons within genotypes, between genotypes, drug treatments, and for comparisons of treatments in the same animal that were sampled at various times.
Results
We initially performed an immunohistochemical analysis of GRK2 expression in the mouse brain to define the global distri- Figure 1 . GRK2 expression in mouse brain. A-C, Brain sections prepared from C57BL/6J mice were immunostained either with a GRK2-specific antibody (anti-GRK2) or with the secondary antibody alone. Representative confocal images of GRK2 immunoreactivity throughout the brain (A), in the CA3 region of the hippocampus (B), or in the dorsal striatum (C) are shown (n ϭ 5 mice). D, Western analyses of GRK2 levels in the FC, dorsal striatum (dSTR), and ventral striatum (VSTR) of C57BL/6J mice. Representative Western blots and the corresponding densitometric analyses are shown. GRK2 levels were normalized to actin in each respective lane. Data are mean ϩ SEM; n ϭ 6 mice for each group. **p Ͻ 0.01 and *p Ͻ 0.05 by unpaired t test. E, Immunofluorescence of dorsal striatal sections prepared from C57BL/6J mice that were costained with antibodies directed against either GRK2 (green) and ChAT (red) (E) or against GRK2 (green) and DARPP-32 (red) (F ). A merge of both fluorescent channels in E and F is shown in the third column. G, Quantification of the number of ChAT-or DARPP-32-positive cells that were also found to be positive for GRK2 in dorsal striatal sections.
bution of this isoform. Sagittal sections prepared from adult C57BL/6J mice were stained with a GRK2-specific antibody. The selectivity of this antibody for GRK2 over other isoforms has been previously demonstrated using purified recombinant GRK proteins (Ahmed et al., 2008a) . GRK2 immunoreactivity was found distributed throughout the brain with the highest levels of expression observed in the CA3 region of the hippocampus and within the molecular layer of the cerebellum (Fig. 1 A) . Highermagnification images revealed the robust expression of GRK2 within the cell bodies of CA3 pyramidal neurons and also what appeared to be labeling in axonal and dendritic compartments (Fig. 1 B) . In contrast, GRK2 expression in the striatum was markedly lower relative to many other regions, with only large, positively stained cell bodies scattered sparsely throughout (Fig.  1 A, C) . Consistent with these observations, GRK2 protein levels in the striatum were significantly reduced relative to the levels found in the frontal cortex (FC vs dorsal striatum, p ϭ 0.058; FC vs ventral striatum, p ϭ 0.0107; Fig. 1 D) . To determine which cell type in the striatum expressed GRK2, we costained sections with either ChAT (a marker for cholinergic neurons) or DARPP-32 (a marker for all medium spiny neurons; Fig. 1 E, F ) . We found that all ChAT-positive neurons were also positive for GRK2, while no colocalization of GRK2 was evident with DARPP-32 (Fig. 1 E-G) . Our results suggest that despite the widespread distribution of this kinase throughout the brain, GRK2 expression within the striatum is highly enriched in cholinergic interneurons.
To better understand the role of GRK2 in cholinergic neurons, we crossed mice with a floxed Grk2 locus (Grk2 ). ChAT IRES-cre mice were also crossed to a Rosa26-floxed-stop-EYFP (R26-EYFP) reporter mouse line to verify Cre-mediated recombination by immunostaining. In agreement with the expected expression pattern, we found that EYFP immunoreactivity was restricted to ChATpositive neurons within the striatum (Fig.  2A) . To determine whether GRK2 was selectively deleted from cholinergic neurons in the conditional KO animals, EYFP and GRK2 costaining was analyzed in ChAT IREScre 
Grk2
f/f R26-EYFP mice. As expected, in control sections prepared from ChAT IREScreR26-EYFP mice, neurons that expressed ChAT also expressed GRK2 (Fig. 2B ). This was in stark contrast to the staining observed in KO animals (ChAT
IRES-cre

Grk2
f/f R26-EYFP), where no GRK2 immunoreactivity was observed in ChAT neurons or throughout the striatum (Fig. 2 B) . These results confirm that KO mice lack GRK2 in cholinergic neurons and further demonstrate the cellular specificity of GRK2 expression in striatal cholinergic interneurons.
Since stimulation of the cholinergic system has been shown to promote hypothermia and hypoactivity, we next wanted to determine whether these central cholinergic responses were altered by the selective deletion of GRK2. We found that core body temperature of ChAT IRES-cre Grk2 f/f mice did not differ from control animals (34.9 Ϯ 0.08°C vs 34.6 Ϯ 0.1°C, respectively) and similarly, no difference was observed in locomotor activity between genotypes in a given 1 h period (1757.2 Ϯ 75.4 cm for control mice vs 1570.0 Ϯ 195 cm for KO mice; Fig. 3 A, B) or in body weight (data not shown). Because GRK2 has classically been shown to be engaged following receptor activation, we next evaluated the behavioral responses of ChAT IRES-cre Grk2 f/f mice to Oxo-M, a nonselective muscarinic acetylcholine receptor agonist. Oxo-Minduced behaviors include hypothermia, hypolocomotion, salivation and antinociception in mice (Gainetdinov et al., 1999) . Oxo-M treatment (0.1 mg/kg, i.p.) produced robust hypothermia in both genotypes (Fig. 3C) ; however, the magnitude of the response was significantly reduced in ChAT
IRES-cre
Grk2
f/f mice (for treatment, F (1,28) ϭ 140.64, p Ͻ 0.0001; interaction, F (1,28) ϭ 12.02, p ϭ 0.0017). While both genotypes also became less active following Oxo-M treatment (0.05 mg/kg, i.p.; Fig. 3D ), the initial response of ChAT IRES-cre Grk2 f/f mice was significantly blunted relative to control animals (interaction, F (5,84) ϭ 2.82, p ϭ 0.0211; genotype, F (1,84) ϭ 6.13, p ϭ 0.0153; interaction genotype ϫ time, Fig. 3D ). In contrast, Oxo-M-induced analgesia was pronounced in both ChAT
IRES-cre
Grk2
f/f and Grk2 f/f mice (Fig. 3F ) , with no difference observed between genotypes (for treatment, F (1,28) ϭ 13.74, p ϭ 0.0009; genotype, F (1,28) ϭ 0.58, p ϭ 0.4540; interaction, F (1,28) ϭ 0.10, p ϭ 0.7569). Together, these data indicate that the deletion of GRK2 from cholinergic neurons does not grossly alter cholinergic function but, rather, reduces sensitivity to select muscarinic acetylcholine receptor-mediated behavioral responses.
Previous studies have reported that the genetic deletion of G-protein-coupled receptor kinase 6 (GRK6) promotes cocaine supersensitivity in mice, while GRK2 heterozygous animals exhibit a very modest enhancement of cocaine-induced locomotor activity (Gainetdinov et al., , 2004 . To determine whether the selective deletion of GRK2 in cholinergic neurons alters behavioral responsiveness to cocaine, locomotor activity was measured following acute or subchronic cocaine administration (Fig. 4) . ChAT
IRES-cre
Grk2
f/f mice given a single injection of cocaine at the indicated doses responded in a similar manner to control animals (interaction, F (23,644) Figure 4A ,B). To determine whether sensitization to cocaine was altered by GRK2 deficiency, we evaluated locomotor activity in Grk2 f/f and ChAT
IRES-cre
Grk2
f/f mice following daily injections of cocaine (20 mg/ kg, i.p.; Fig. 4C-E) . The initial response of both genotypes to cocaine (day 1) did not differ significantly (interaction, F (23,322) ϭ 0.64, p ϭ 0.8978; genotype, F (1,322) ϭ 5.54, p ϭ 0.0337; time, F (23,322) ϭ 13.54, p Ͻ 0.0001) at all times evaluated with the exception of the time of peak response ( p Ͻ 0.5 by Bonferroni post hoc test) (Fig. 4C,  left) . Repeated cocaine injections produced robust sensitization with no observed differences between genotypes on day 7 (interaction, F (23, 322) ϭ 0.97, p ϭ 0.4993; genotype, F (1,322) ϭ 0.01, p ϭ 0.9209; time, F (23,322) ϭ 18.79, p Ͻ 0.0001; Fig. 4C, right) . Analysis of the sum of the total distance traveled in the 10 min postinjection of cocaine revealed a significant increase in activity in both genotypes on day 7, but no significant difference in the activity of ChAT IRES-cre Grk2 f/f mice relative to control animals was found (interaction, F (1,14) ϭ 1.99, p ϭ 0.1802; genotype, F (1, 14) ϭ 0.01, p ϭ 0.9117; time, F (1,14) ϭ 10.59, p ϭ 0.0058) (Fig. 4 D) . Last, a conditioned place preference paradigm was used to determine whether the rewarding properties of cocaine were affected by the selective deletion of GRK2. In these studies we observed a similar level of preference in both genotypes at the two doses of cocaine tested (Fig. 4 E) . Collectively, these results suggest that GRK2 deficiency in cholinergic neurons does not alter cocaine-induced psychomotor activation, sensitization, or the rewarding properties of the drug.
Discussion
The lack of viable GRK2 KO mice has proven to be a significant obstacle in the study of the function of this kinase in the adult brain. Additionally, the scarcity of information regarding the distribution of GRK2 in various cell populations has prevented more directed genetic studies. Here we report the expression of GRK2 in the mouse brain and identify the principal cell type in which this isoform is expressed within the striatum. These expression results confirm and extend a previous report on GRK2 In our study we found that cocaine promotes similar levels of locomotor activity, behavioral sensitization and conditioned place preference in conditional KO animals relative to control animals. These results suggest that GRK2 function within cholinergic neuronal populations does not regulate dopaminergic signaling.
In summary, our results demonstrate that the loss of GRK2 in cholinergic neurons leads to markedly reduced behavioral sensitivity to muscarinic receptor stimulation. Considering the supersensitivity to muscarinic agonists observed in GRK5-deficient animals, it would appear that the GRK2 family member has a unique functional role in that it positively regulates central cholinergic responses. Given that hypercholinergic tone is associated with several movement disorders, such as Parkinson's disease and dystonia, this functional divergence between isoforms may be exploited in future work to explore the therapeutic potential of selective GRK2 inhibitors.
